Table 4.
Most common TEAEs (occurring in ≥10% of patients) during the IND and OP/M phases of SUSTAIN-3
| TEAEs | n (%) |
|---|---|
| IND phase (N = 96) | |
| ≥10% TEAE | 56 (58.3) |
| Dissociation | 17 (17.7) |
| Dizziness | 13 (13.5) |
| Vertigo | 13 (13.5) |
| Dysgeusia (bitter taste) | 12 (12.5) |
| OP/M phase (N = 94) | |
| ≥10% TEAE | 80 (83.3) |
| Dissociation | 26 (27.1) |
| Headache | 24 (25.0) |
| Dizziness | 21 (21.9) |
| Vertigo | 20 (20.8) |
| Somnolence | 18 (18.8) |
| Nausea | 18 (18.8) |
| Nasopharyngitis | 17 (17.7) |
| Anxiety | 16 (16.7) |
| Dysgeusia (bitter taste) | 15 (15.6) |
| Blood pressure increased | 13 (13.5) |
| Influenza | 11 (11.5) |
| Upper respiratory tract infection | 10 (10.4) |
| Urinary tract infection | 10 (10.4) |
| Vision blurred | 10 (10.4) |
IND induction, OP/M optimization/maintenance phase, TEAE treatment-emergent adverse event